{"id":385418,"date":"2020-11-19T12:33:16","date_gmt":"2020-11-19T17:33:16","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=385418"},"modified":"2020-11-19T12:33:16","modified_gmt":"2020-11-19T17:33:16","slug":"glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\/","title":{"rendered":"Glancy Prongay &amp; Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals,  Inc. (BMRN)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"both\">LOS ANGELES, Nov.  19, 2020  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gW_cki9Kyb6MXAW0KQjf_AIVRTdljykbFHIqHj1LE8ZcgZXE56uxnm7rKsEXPJOSDYIMEHP-Eu3a0zmBevGU5gtZm5HpniLvhWZc1sbFswA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Glancy Prongay &amp; Murray LLP<\/a> (\u201cGPM\u201d) reminds investors of the upcoming\u00a0<strong>November 24<\/strong><strong>, 2020 <\/strong>deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired BioMarin Pharmaceuticals, Inc. (\u201cBioMarin\u201d or the \u201cCompany\u201d) (NASDAQ: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CONeYJkzTXlB9rNCHW_7KWbFGOmgMFizmruwAAEltCHXR5GVFv5ymE1X5tTOKdzWkHbGZjTvwklZZaD02dCjkQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">BMRN<\/a>) securities between <strong>February 28, 2020 and August 18, 2020<\/strong>, inclusive (the \u201cClass Period\u201d).<\/p>\n<p>If you suffered a loss on your BioMarin investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at \u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UNV9Qgte7mCuHDa8MM3Gkk8fNAihidRxOHd9K0x2rGXdsVwwUWXMr0OmX12bYdmVwTFTbbTotki3ZvGxAdfc6Cgh1cbVtwX_Mfcu_GNwCAyVmdzewUYmFy7I0LTORBOIySSMY24o_fW-YPqqUVA8y8Bt0pOYVMPXcktv7BNNfh2ucl4edIhnnncXmlaL4RNb\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>https:\/\/www.glancylaw.com\/cases\/biomarin-pharmaceuticals-inc\/<\/u><\/a>. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wxRo5xVh8Ocn6IK0iMG9kA5Rg7FBgGe_hkkk0b3M43zHK5aJnScPvjgCv7jXH7zyocn2MtALUcXp09VAydwd0WdfqFQ8JZtbLj3OtyXW6SJAdMhVvJ5mPGunDHnIUA-H\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">shareholders@glancylaw.com<\/a> to learn more about your rights.<\/p>\n<p>BioMarin is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The Company&#8217;s product candidates include,\u00a0as well as\u00a0others, valoctocogene roxaparvovec, an investigational adeno-associated virus (&#8220;AAV&#8221;) gene therapy, which is in Phase 3 clinical development for the treatment of patients with severe hemophilia A.\u202f\u00a0<\/p>\n<p>On August 19, 2020, BioMarin announced receipt of a Complete Response Letter (\u201cCRL\u201d) from the U.S. Food and Drug Administration (\u201cFDA\u201d) regarding the Company\u2019s Biologics License Application (\u201cBLA\u201d) for valoctocogene roxaparvovec. Therein, the FDA concluded that the \u201cdifferences between Study 270-201 (Phase 1\/2) and the Phase 3 study limited its ability to rely on the Phase 1\/2 study to support durability of effect.\u201d As a result, the FDA recommended that BioMarin \u201ccomplete the Phase 3 Study and submit two-year follow-up safety and efficacy data on all study participants.\u201d<\/p>\n<p>On this news, the Company\u2019s stock price fell $41.82 per share, or 35%, to close at $76.72 per share on August 19, 2020, thereby injuring investors.<\/p>\n<p>The\u00a0complaint\u00a0filed in this class action alleges that throughout the Class Period,\u00a0Defendants made materially false and\/or misleading statements and\/or failed to disclose\u00a0material adverse facts about the Company\u2019s business, operations, and prospects. Specifically, Defendants failed to disclose to investors\u00a0that:\u00a0(1) the\u00a0disparities between the Phase 1\/2 and Phase 3 study of valoctocogene roxaparvovec limited the reliability of the Phase 1\/2 study to support valoctocogene\u00a0roxaparvovec&#8217;s\u00a0durability of effect; (2) as a result, it was foreseeable that the FDA would not approve the BLA for valoctocogene roxaparvovec without additional data;\u00a0and (3) that, as a result of the foregoing, Defendants\u2019 positive statements about the Company\u2019s business, operations, and prospects were materially misleading and\/or lacked a reasonable basis.\u00a0\u00a0<\/p>\n<p>Follow us for updates on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jAsjOnYbn4Sr9QaRxQfjG6iWZdJD1zhXBXA0OaPbrruMacCsFhHiPp5NcCOiFs1ZKkUN3sQhQa599gp7KzQOaT_VkvALeqsXmpFSCTKLmeCcJlW1kXgQEJBW3aecUh3q\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dE010jTYHeW1ZzUcbrlfn65D19URAkporMpb1WcPpQT_KgoOAFKr8dWWwqdEO7gAVGpIlL6F-c2yPr5TtZCeIQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Twitter<\/a>, or <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fs2dyhzuWXc9zN_vWEl0GSZCwBtx_6QkPfVKnFgvwZ8bxnoY3On6b1GLxaw1krmuydLhi2oUz-hR-udNshXPKTtjatzl4opSZNKBsjYSZ38=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p>If you purchased or otherwise acquired BioMarin securities during the Class Period, you may move the Court no later than <strong>November 24<\/strong><strong>,<\/strong><strong> 2020 <\/strong>to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to\u00a0learn more\u00a0about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wxRo5xVh8Ocn6IK0iMG9kA5Rg7FBgGe_hkkk0b3M43xFBg_1U7ur13BoHP-MuRcIT1SCsLPagqBIov_LitOtcCCSPdYJd-GqROy8l_UB9_qM5y0SXWUsaQIwoPJgoR8a\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">shareholders@glancylaw.com<\/a>, or visit our website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vkmubu9Q81CgvlvG-zpVu8SKgEhfg_Lm9Kyett1atoO2_wu218Wn4oCYC9CuR5SvL_ee8px5y6oy3eJKdN450g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.glancylaw.com<\/a>. If you inquire by email please include your mailing address, telephone number and number of shares purchased.<\/p>\n<p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p>\n<p>\n        <strong>Contacts<\/strong><br \/>\n        <br \/>Glancy Prongay and Murray LLP, Los Angeles<br \/>Charles Linehan, 310-201-9150 or 888-773-9224<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vkmubu9Q81CgvlvG-zpVu5UFe6Ebhj9Ak8JzMjejdKyHbHD25XOEE8MS__TuievM7PoEEsua1W4ZqIAC-KzuZpIbKEfzccFZARexPmQVAIU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.glancylaw.com<\/a>\u00a0\u00a0 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wxRo5xVh8Ocn6IK0iMG9kA5Rg7FBgGe_hkkk0b3M43yx12ix1uvH88Z4FlYW4fVsdtpHdZOBSZi4bxNnLT7egbDdXYkAS2OB1law2-9ZUNR3pi0xMH0sbSgCk5GWH5bX\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">shareholders@glancylaw.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODcyNiMzODM0NDA0IzIwMTcyOTE=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/66d510b3-d766-48a6-9a6a-766ce4393bf5\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LOS ANGELES, Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; Glancy Prongay &amp; Murray LLP (\u201cGPM\u201d) reminds investors of the upcoming\u00a0November 24, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired BioMarin Pharmaceuticals, Inc. (\u201cBioMarin\u201d or the \u201cCompany\u201d) (NASDAQ: BMRN) securities between February 28, 2020 and August 18, 2020, inclusive (the \u201cClass Period\u201d). If you suffered a loss on your BioMarin investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at \u00a0https:\/\/www.glancylaw.com\/cases\/biomarin-pharmaceuticals-inc\/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Glancy Prongay &amp; Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals,  Inc. (BMRN)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-385418","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Glancy Prongay &amp; Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals, Inc. (BMRN) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Glancy Prongay &amp; Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals, Inc. (BMRN) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LOS ANGELES, Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; Glancy Prongay &amp; Murray LLP (\u201cGPM\u201d) reminds investors of the upcoming\u00a0November 24, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired BioMarin Pharmaceuticals, Inc. (\u201cBioMarin\u201d or the \u201cCompany\u201d) (NASDAQ: BMRN) securities between February 28, 2020 and August 18, 2020, inclusive (the \u201cClass Period\u201d). If you suffered a loss on your BioMarin investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at \u00a0https:\/\/www.glancylaw.com\/cases\/biomarin-pharmaceuticals-inc\/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn &hellip; Continue reading &quot;Glancy Prongay &amp; Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals, Inc. (BMRN)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-19T17:33:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODcyNiMzODM0NDA0IzIwMTcyOTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Glancy Prongay &amp; Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals, Inc. (BMRN)\",\"datePublished\":\"2020-11-19T17:33:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\\\/\"},\"wordCount\":617,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODcyNiMzODM0NDA0IzIwMTcyOTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\\\/\",\"name\":\"Glancy Prongay &amp; Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals, Inc. (BMRN) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODcyNiMzODM0NDA0IzIwMTcyOTE=\",\"datePublished\":\"2020-11-19T17:33:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODcyNiMzODM0NDA0IzIwMTcyOTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODcyNiMzODM0NDA0IzIwMTcyOTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Glancy Prongay &amp; Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals, Inc. (BMRN)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Glancy Prongay &amp; Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals, Inc. (BMRN) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\/","og_locale":"en_US","og_type":"article","og_title":"Glancy Prongay &amp; Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals, Inc. (BMRN) - Market Newsdesk","og_description":"LOS ANGELES, Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; Glancy Prongay &amp; Murray LLP (\u201cGPM\u201d) reminds investors of the upcoming\u00a0November 24, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired BioMarin Pharmaceuticals, Inc. (\u201cBioMarin\u201d or the \u201cCompany\u201d) (NASDAQ: BMRN) securities between February 28, 2020 and August 18, 2020, inclusive (the \u201cClass Period\u201d). If you suffered a loss on your BioMarin investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at \u00a0https:\/\/www.glancylaw.com\/cases\/biomarin-pharmaceuticals-inc\/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn &hellip; Continue reading \"Glancy Prongay &amp; Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals, Inc. (BMRN)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-19T17:33:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODcyNiMzODM0NDA0IzIwMTcyOTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Glancy Prongay &amp; Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals, Inc. (BMRN)","datePublished":"2020-11-19T17:33:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\/"},"wordCount":617,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODcyNiMzODM0NDA0IzIwMTcyOTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\/","name":"Glancy Prongay &amp; Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals, Inc. (BMRN) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODcyNiMzODM0NDA0IzIwMTcyOTE=","datePublished":"2020-11-19T17:33:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODcyNiMzODM0NDA0IzIwMTcyOTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODcyNiMzODM0NDA0IzIwMTcyOTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-biomarin-pharmaceuticals-inc-bmrn-4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Glancy Prongay &amp; Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals, Inc. (BMRN)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/385418","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=385418"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/385418\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=385418"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=385418"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=385418"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}